A5053034607- Cancer Treatment and Pharmacology
- Colorectal Cancer Treatments and Studies
- Lung Cancer Treatments and Mutations
- Breast Cancer Treatment Studies
- Gastric Cancer Management and Outcomes
- Advanced Breast Cancer Therapies
- Hepatocellular Carcinoma Treatment and Prognosis
- Genetic factors in colorectal cancer
- Cancer Genomics and Diagnostics
- Colorectal and Anal Carcinomas
- Lymphoma Diagnosis and Treatment
- Lung Cancer Diagnosis and Treatment
- Ovarian cancer diagnosis and treatment
- Cancer therapeutics and mechanisms
- Cancer Diagnosis and Treatment
- HER2/EGFR in Cancer Research
- Bone health and treatments
- Molecular Biology Techniques and Applications
- Sarcoidosis and Beryllium Toxicity Research
- Intraperitoneal and Appendiceal Malignancies
- Biliary and Gastrointestinal Fistulas
- Biomedical Research and Pathophysiology
- RNA Research and Splicing
- PARP inhibition in cancer therapy
- Growth Hormone and Insulin-like Growth Factors
Hospital Universitario de Móstoles
2007-2019
Bellvitge University Hospital
2015
Central University of the Caribbean
2013
Hospital Costa del Sol
2011
Institut Català d'Oncologia
2010
Complejo Hospitalario de Ourense
2010
Hospital Son Llatzer
2009
Hospital Universitario Príncipe de Asturias
2009
Hospital Universitario Puerta del Mar
2009
Hospital Universitario Virgen de las Nieves
2006
Although chemotherapy is the cornerstone treatment for patients with metastatic colorectal cancer (mCRC), acquired chemoresistance common and constitutes main reason failure. Monoclonal antibodies against insulin-like growth factor-1 receptor (IGF-1R) have been tested in pre-treated mCRC patients, but results largely deceiving. We analysed time to progression, overall survival, mutational status of RAS, BRAF nuclear p-IGF-1R expression by immunohistochemistry, 470 CRC patients. The effect...
Purpose Current therapies fail to cure a significant proportion of patients with Hodgkin's lymphoma (HL). Predictive systems for stratification the disease and selection treatment based on sets clinical variables, such as international prognostic score (IPS), are relatively small practical value. The predictive use biologic parameters has so far provided limited inconsistent results. Here we explore influence set molecular markers outcome HL. Patients Methods Forty involved in B-cell...
Abstract Purpose: Despite major advances in the treatment of classic Hodgkin's lymphoma (cHL), ∼30% patients advanced stages may eventually die as result disease, and current methods to predict prognosis are rather unreliable. Thus, application robust techniques for identification biomarkers associated with response is essential if new predictive tools be developed. Experimental Design: We used gene expression data from cHL identify transcriptional patterns tumoral cells their nonneoplastic...
This phase II study aims to evaluate the efficacy and safety of biweekly cetuximab in combination with oxaliplatin, leucovorin, fluorouracil (FOLFOX-4) as first-line treatment metastatic wild-type KRAS colorectal cancer. Previously untreated patients tumours received (500 mg/m2 on day 1) plus FOLFOX-4 (oxaliplatin 85 1, leucovorin 200 days 1 2, a 400 bolus followed by 22-hour 600 infusion 2). Treatment was continued until disease progression, onset unacceptable toxicities, metastases...
RAS and BRAF mutations can be detected as a mechanism of acquired resistance in circulating tumor (ct) DNA patients with metastatic colorectal cancer treated anti-epidermal growth factor receptor therapy.RAS mutational status was assessed ctDNA baseline plasma sample serum collected at the time last available determination (named secondary extraction) from KRAS exon 2 wild-type two first-line prospective biomarker-designed clinical trials (PULSE, ClinicalTrials.gov identifier: NCT01288339;...
<i>Background:</i> We gathered data from multiple institutions on the cetuximab regimen of patients with metastatic colorectal cancer. <i>Methods:</i> 126 19 centers were included July 2006 to 2007 in this prospective non-controlled study. Irinotecan-refractory cancer Karnofsky ≧70 received 500 mg/m<sup>2</sup> every 2 weeks (q2w) combination irinotecan 180 q2w until disease progression or unacceptable toxicity. The primary endpoint was progression-free...
A 54-year-old male, insulin-dependent diabetic and chronic kidney disease stage I, was brought to Emergency Department with a complaint of acute vision loss, severe hypoglycemia, hyperventilation, metabolic acidosis renal failure. Five days prior admission suffered diarrhea vomiting loss at the last 12 h. Home medications included insulin lantus, valsartan 160 mg, amlodipine 5 mg metformin 850 mg twice day. There not previous history drinking alcohol, smoking or drugs abuse. In emergency...
Abstract Background RAS testing is used to select patients with anti-epidermal growth factor receptor (EGFR) therapies sensitivity in metastatic colorectal cancer (mCRC). However, other biomarkers such as BRAF, PIK3CA/PTEN, and p-IGF-1R+/MMP7+ (double positive [DP] phenotype) have not been prospectively assessed predict anti-EGFR resistance. Materials Methods We designed a multicenter prospective trial (NCT01276379) evaluate whether the BRAF mutation, PIK3CA mutation/PTEN loss, DP phenotype...
INTRODUCTION: The coexpression of pIGF-1R and MMP-7 (double-positive phenotype, DP) correlates with poor overall survival (OS) in KRAS wild-type (WT) (exon 2) metastatic colorectal cancer (mCRC) patients treated irinotecan-cetuximab second/third line. METHODS: We analyzed two prospective biomarker design trials newly diagnosed RAS-WT mCRC panitumumab-FOLFOX6 (PULSE trial; NCT01288339) or cetuximab plus either FOLFOX6/FOLFIRI (POSIBA NCT01276379). main exposure was DP phenotype (DP/non-DP),...
BACKGROUND The purpose of this study was to analyze whether the addition granulocyte-colony stimulating factor (G-CSF) platinum-based combination chemotherapy could increase platinum dose intensity and response rates decrease hematologic toxicity in patients with advanced epithelial ovarian carcinoma. METHODS Patients untreated carcinoma (International Federation Gynecology Obstetrics [FIGO] Stage IIC-IV) were treated after maximum debulking surgery cyclophosphamide, 750 mg/m2, carboplatin,...
756 Background: To evaluate the efficacy and toxicity profile of VNR LTZ in aged women with MBC. Methods: Between April 2001 August 2003, fifty-three measurable MBC, no prior chemotherapy for advanced disease, ECOG performance status (PS) 0–1, adequate bone marrow, renal hepatic function were included. Twenty-four pts had been treated neo/adjuvant therapy, 16 them chemotherapy. Only five patients received hormonal therapy as first line treatment Treatment consists 30 mg/m2 i.v. on days 1 8...
19109 Background: Bevacizumab (B) has been shown to improve response rates and survival in pts with advanced non-squamous NSCLC when combined carboplatin paclitaxel (FDA & EMEA-approved indication) or cisplatin gemcitabine (EMEA-approved). However, there are limited data on the safety efficacy of B combination other widely used chemotherapy doublets for NSCLC. This is a preliminary report single-arm, open-labeled, phase II trial B, docetaxel Methods: In this single-stage trial, patients...
3547 Background: In a previous phase II trial in ACC, an all-oral regimen of Tegafur and Leucovorin obtained overall response rate 30% (Cancer,1998;83:254–8). We conducted multicenter randomized equivalence patients with to compare oral (FT) + (LV) the Mayo schedule. Methods: Patients locally advanced or metastatic colorectal adenocarcinoma who were not candidates for radical therapy, randomly assigned treatment if they had KPS ≥ 60%, measurable evaluable disease, adequate bone marrow, liver...
e19023 Background: Bevacizumab (B), in addition to platinum-based chemotherapy, is indicated for 1st-line treatment of p with advanced NSCLC other than predominantly squamous cell histology. B has been shown improve progression free survival (PFS) and overall (OS) when combined cisplatin/gemcitabine carboplatin/paclitaxel, respectively. However, there are limited data on the safety efficacy combination widely used chemotherapy doublets NSCLC. This a single-arm, open- labeled, single-stage...